BioCentury | Nov 12, 2020
Finance

Nov. 11 Quick Takes: Adagio raises $80M for COVID-19 antibody; plus venture investments for Congenica, CoImmune, Trailhead, Doer Biologics, Protomer and more

...activity” that can be controlled using small molecules. The company said it has a glucose-responsive insulin...
BioCentury | Nov 7, 2020
Translation in Brief

Neoleukin’s ACE2 decoy protects hamsters from SARS-CoV-2; plus a circular RNA linked to diabetes and more

...which had EC50 values below 5 nM in cell-based assays, into the clinic.Circular RNA promotes insulin...
...article in Nature Communications has implicated in diabetes reduced levels of a circular RNA generation from an insulin...
...rat islets that silencing the circular RNA decreased expression of β cell secretory machinery components and impaired insulin...
BioCentury | Oct 31, 2020
Translation in Brief

A method to collect tumor-specific T cells; plus research from Heidelberg University, Black Diamond, KSQ and SynDevRx

...an Akt/mTOR inhibitor, or with Piqray alpelisib, a PI3Kɑ inhibitor from Novartis AG (NYSE:NVS; SIX:NOVN). SDX-7320 also restored insulin...
BioCentury | Oct 29, 2020
Product Development

Flagship’s Senda builds on Kintai’s microbe-mimicking pipeline with plant and bacteria-based delivery modalities

...antisense oligos, mRNA and peptides such as insulin.He...
BioCentury | Oct 15, 2020
Emerging Company Profile

RayzeBio pulling together radiotherapy platform with $45 million

...Epidermal growth factor receptor 2 IGF1R (CD221) – Insulin-like...
BioCentury | Sep 30, 2020
Distillery Therapeutics

Endogenous bile acid identified for obesity and diabetes

...induced GLP-1 secretion. In mice with diet-induced obesity, cholic acid-7-sulfate reduced blood glucose levels, increased insulin...
BioCentury | Sep 30, 2020
Distillery Therapeutics

Islet-like organoids expressing PD-L1 for diabetes

...Type I diabetes. The organoids were generated by engineering human iPS cells to express an insulin...
BioCentury | Sep 30, 2020
Product Development

Partner Amgen becomes investor as Carmot pushes diabetes therapies ahead with $47M series C

...gastric emptying and nausea to heart rate, insulin...
...both hormones such as satiety and improved insulin...
BioCentury | Sep 26, 2020
Politics, Policy & Law

Trump policies mark a turning point in debate over U.S. drug price controls

...drug importation, discounts for seniors, and low-cost insulin...
...motion a policy that could provide low-cost insulin...
...is working on a funding plan. Discounted insulin/epinephrineUnder...
BioCentury | Sep 1, 2020
Product Development

Aug. 31 Quick Takes: Mylan, Biocon launch cheaper insulin in U.S.; plus: AZ, bluebird, Lipocine, Amgen, AbbVie-Morphic, Polyphor-Fosun and Milestone

...launch long-acting insulin biosimilar in U.S.Mylan N.V. (NASDAQ:MYL) and Biocon Ltd. (NSE:BIOCON; BSE:532523) launched Semglee insulin...
...10 mL vial, which the companies said is the lowest WAC for a marketed long-acting insulin...
...adults and children with Type I diabetes (see “Biocon, Mylan Insulin Product Could Herald Cheaper Insulin...
Items per page:
1 - 10 of 4797